Mast Cell–Stabilizing Medications Explained
When “Normal” Doses Don’t Feel Like Enough
If you live with MCAS, you’ve probably been told that your reactions are “allergies” — or worse, that nothing is really wrong. But mast cell disease is not a typical allergy. It’s a pattern of overactive immune signaling that often needs more consistent, targeted support.
Medication can be life-changing when it’s chosen thoughtfully and introduced safely.
Why MCAS Often Needs Daily Support
Mast cells don’t just flare once and settle down. They stay primed and reactive. That’s why treatment usually focuses on prevention, not just rescue. Stabilizing mast cells reduces the frequency and severity of flares instead of only treating symptoms after they start.
Consistency matters.
H1 & H2 Blockers: The Foundation
Most MCAS treatment plans start with two classes of antihistamines:
- H1 blockers – cetirizine (Zyrtec), loratadine (Claritin), levocetirizine (Xyzal) and fexofenadine (Allegra)
- H2 blockers – famotidine (Pepcid), cimetidine (Tagamet), and nizatidine (Axid AR)
Using both together often works better than either one alone. In MCAS, providers may prescribe doses higher than standard “allergy” dosing — because this isn’t a simple allergy condition.
There are many options in each class. If one doesn’t work for you, another might.
When Antihistamines Aren’t Enough
Some people need additional mast cell–stabilizing medications. These are not rescue drugs — they are meant to calm mast cells over time.
- Cromolyn sodium can help stabilize the gut and reduce food-triggered reactions.
- Montelukast can reduce inflammatory signaling and breathing symptoms.
- Biologic medications such as omalizumab (Xolair) may be used for more severe or persistent cases.
Each option has specific benefits, risks, and dosing strategies that require careful guidance.
Go Slow, Always
MCAS bodies react strongly — even to helpful treatments. Starting low and increasing slowly can prevent flares and make medications more tolerable. What works beautifully for one person may not feel right for another.
This is not a race. It’s a process.
Always Work With a Knowledgeable Provider
Never start, stop, or change medications or supplements without guidance from a provider experienced in MCAS and hypermobility-related conditions. This protects your safety and helps build a plan that actually supports your body long term.
The Takeaway
MCAS care is not about taking “more.”
It’s about taking what’s right for your body, in the right way, at the right pace.
Relief is possible — and it can be built gently.
Share Your Story
Have you found a medication that made a real difference in your flares or daily symptoms? What helped you most along the way?
Connect with Us
Follow us on social media for more tips, updates, and support:
Ready to Take the Next Step?
For those seeking personalized guidance, our 1-on-1 coaching program offers tailored support to address your specific needs. With expert advice and a comprehensive plan, you’ll gain the tools and confidence to manage your condition effectively. Learn more and sign up here.
Thank you for being part of the Bendy Club. Together, we can make a difference!
Warm regards,
The Hypermobile Solutions Team
References
Home. The Ehlers Danlos Society. https://www.ehlers-danlos.com/
What is HSD?. The Ehlers Danlos Society. https://www.ehlers-danlos.com/what-is-hsd/
What is eds?. The Ehlers Danlos Society. https://www.ehlers-danlos.com/what-is-eds/
Jovin, D., Atwal, P., Herman, K., Block, N., Maxwell, A. J., Mitakides, J., Maitland, A. M., Saperstein, D., Hamilton, M., Schofield, J., Koby, M., Klinge, P., McElroy, A., Bluestein, L., Chopra, P., Tishler, J., Pocinki, A. G., Varga, J., Dempsey, T., … Lane, K. (2020). Disjointed: Navigating the diagnosis and management of Hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Hidden Stripes Publications, Inc.
Smith, C., & Wicks, D. (2017). Understanding Hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder: (previously known as Ehlers-Danlos Syndrome Hypermobility Type & Joint Hypermobility Syndrome, respectively). Redcliff-House Publications.
Cox, C. (2022). Holding it all together when you’re Hypermobile. Journey2Joy
Afrin, L. B. (2016). Never bet against Occam: Mast cell activation disease and the modern epidemics of chronic illness and medical complexity. Sisters Media, LLC.
Freeman, K., Goldstein, D. S., & Thompson, C. R. (2025). The dysautonomia project: Understanding autonomic nervous system disorders (2nd ed.). Bardolf.
Disclaimer
This blog is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no provider/patient relationship is formed. The use of information on this blog or materials linked from this blog is at the user’s own risk. The content of this blog is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.